A recent study compared the predictive performance of three imaging models in order to determine the most accurate noninvasive method for diagnosing MASH.
A recent clinical trial showed that probiotic supplementation in patients with early-stage NASH/MASH did not significantly improve liver or clinical parameters.
A unique set of cytokine and chemokine markers could serve as biomarkers to differentiate non-alcoholic steatohepatitis from non-alcoholic fatty liver disease.
Understanding patient experiences with MASH symptoms and their effect on day to-day life can enhance patient-clinician discussions and facilitate patient-centered treatment and disease management, according to a real-world,...